Earlier this month, the Federal Circuit decided a subject matter eligibility case closely watched in the pharmaceutical industry. The case involved composition-of-matter claims reciting measured results. Reversing the decision below, the court ruled that the claims were directed to concrete structures, not patent-ineligible abstract ideas.
